SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-259617
Filing Date
2020-09-30
Accepted
2020-09-30 16:08:54
Documents
14
Period of Report
2020-09-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d58361d8k.htm   iXBRL 8-K 34762
2 EX-99.1 d58361dex991.htm EX-99.1 11304
6 GRAPHIC g58361g46v91.jpg GRAPHIC 2764
  Complete submission text file 0001193125-20-259617.txt   184489

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gthx-20200924.xsd EX-101.SCH 3088
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20200924_lab.xml EX-101.LAB 18908
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20200924_pre.xml EX-101.PRE 11875
7 EXTRACTED XBRL INSTANCE DOCUMENT d58361d8k_htm.xml XML 3478
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 201212351
SIC: 2834 Pharmaceutical Preparations